Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | A161V |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | TP53 A161V lies within the DNA-binding domain of the Tp53 protein (PMID: 21232794). A161V does not result in decreased drug-induced apoptosis compared to wild-type Tp53 (PMID: 12726864), and results in interaction with Tbk1 and decreased Tbk1 and Irf3 phosphorylation and loss of Irf3 activation in culture (PMID: 33545063), but has not been fully biochemically characterized and therefore, its effect on Tp53 protein function is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 exon5 TP53 A161V |
Transcript | NM_000546.6 |
gDNA | chr17:g.7675130G>A |
cDNA | c.482C>T |
Protein | p.A161V |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001126114.2 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_000546.5 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_001126113.2 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_001407264.1 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_001407262.1 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_000546 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_001126114.3 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_001407270.1 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_001126114 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_000546.6 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_001126112 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_001126113 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_001126112.3 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_001407266.1 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_001126112.2 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_001407268.1 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
NM_001126113.3 | chr17:g.7675130G>A | c.482C>T | p.A161V | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|